Intensity Therapeutics In... (INTS)
2.35
0.09 (3.98%)
At close: Feb 28, 2025, 3:59 PM
2.34
-0.43%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 2.12 |
| Market Cap | 35.5M |
| Revenue (ttm) | 308.8K |
| Net Income (ttm) | -17.79M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -2.2 |
| Forward PE | -1.95 |
| Analyst | Buy |
| Ask | 2.39 |
| Volume | 8,134 |
| Avg. Volume (20D) | 38,816 |
| Open | 2.20 |
| Previous Close | 2.26 |
| Day's Range | 2.15 - 2.36 |
| 52-Week Range | 1.50 - 5.94 |
| Beta | 5.17 |
About INTS
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & D...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2023
Employees 5
Stock Exchange NASDAQ
Ticker Symbol INTS
Analyst Forecast
According to 3 analyst ratings, the average rating for INTS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 261.70% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
2 months ago
-12.34%
Intensity Therapeutics shares are trading lower. T...
Unlock content with
Pro Subscription
